跳至主要内容
临床试验/NL-OMON24959
NL-OMON24959招募中不适用

Reduce Bladder Cancer Recurrence In Patients Treated For Upper Urinary Tract Urothelial Carcinoma

Erasmus university Medical Center0 个研究点目标入组 170 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
170

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histologically proven urothelial carcinoma of the upper urinary tract with or without concurrent carcinoma in situ (CIS only is allowed) or patients with a suspicion of a urothelial carcinoma of the UUT on CT-scan plus a urinary cytology sample showing high-grade urothelial carcinoma;
  • -Patients planned to be treated either by partial ureterectomy or by a radical nephro-ureterectomy (open or laparoscopic) including a bladder cuff;

排除标准

  • - If pre-operative histology by biopsy shows aberrant histology of the UUT tumor of >50% (adenocarcinoma, small cell carcinoma, squamous cell carcinoma).
  • - History or presence of a malignant tumor or carcinoma in situ of the bladder.

研究者

相似试验

进行中(未招募)
1 期
REduce BlAdder CAncer REcurrence in patients treated for upper urinary tract urothelial carcinoma (REBACARE Trial)pper Tract Urothelial Carcinoma (UTUC).MedDRA version: 20.0Level: HLGTClassification code 10038364Term: Renal and urinary tract neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10038365Term: Renal and urinary tract therapeutic proceduresSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2017-000949-53-NLErasmus MC, Dept. Urology190
已完成
4 期
REduce BlAdder CAncer REcurrence in patients treated for upper urinary tract urothelial carcinoma (REBACARE Trial)urothelial cancer of the upper urinary tractUrothelial carcinoma of the upper urinary tract1003836410046400
NL-OMON50424Erasmus MC, Universitair Medisch Centrum Rotterdam190
进行中(未招募)
1 期
Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy - TOMBOLArothelial cancer
CTIS2024-510865-41-00Aarhus Universitetshospital282
招募中
不适用
Prevention of TaT1 bladder cancer by BCG instillation: Induction alone versus induction and maintenancebladder cancer
JPRN-UMIN000009508Department of Urology and Andrology, Kansai Medical university160
进行中(未招募)
不适用
TREATMENT OF NON-INVASIVE BLADDER CANCER WITH HIGH RISK OF RECURRENCE – BLUE LIGHT CYSTOSCOPY WITH CHEMOTHERAPYbladder cancer (non-invasive Ta urothelial bladder cancer)
EUCTR2012-000559-15-FIFinnBladder